Challenges and recommendations for the management of asthma in the Middle East and Africa

Mohamed Omar Zeitouni 1, Mohamed Saad Al-Moamary 2, Marie Louise Coussa 3, Moussa Riachy 4, Bassam Mahboub 5, Fatma AlHuraish 6, Mohamed Helmy Zidan 7, Mohamed Mostafa Metwally 8, Kurtuluş Aksu 9, Erdinç Yavuz 10, Ismail Sikander Kalla 11, Jeremiah Chakaya 12, Snouber Abdelmadjid 13, Habib Ghedira 14

Affiliations

04 January 2022

-

doi: 10.4103/atm.atm_469_21

Free PMC article

Abstract

Clinical presentation of asthma is variable, and its diagnosis can be a major challenge in routine health-care practice, especially in low-and-middle-income countries. The aim of asthma management is to achieve optimal asthma control and to reduce the risk of asthma exacerbations and mortality. In the Middle East and in Africa (MEA), several patient- and physician-related factors lead to misdiagnosis and suboptimal management of asthma. A panel of experts comprising of specialists as well as general health-care professionals met to identify challenges and provide recommendations for the management of asthma in MEA. The major challenges identified for diagnosis of asthma were lack of adequate knowledge about the disease, lack of specialized diagnostic facilities, limited access to spirometry, and social stigma associated with asthma. The prime challenges for management of asthma in MEA were identified as overreliance on short-acting β-agonists (SABAs), underprescription of inhaled corticosteroids (ICS), nonadherence to prescribed medications, and inadequate insurance coverage for its treatment. The experts endorsed adapting the Global Initiative for Asthma guidelines at country and regional levels for effective management of asthma and to alleviate the overuse of SABAs as reliever medications. Stringent control over SABA use, discouraging over-the-counter availability of SABA, and using as-needed low-dose ICS and formoterol as rescue medications in mild cases were suggested to reduce the overreliance on SABAs. Encouraging SABA alone-free clinical practice in both outpatient and emergency department settings is also imperative. We present the recommendations for the management of asthma along with proposed regional adaptations of international guidelines for MEA.

Keywords: Asthma; Global Initiative for Asthma; inhaled corticosteroids; management; overreliance; short-acting β-agonists.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1 Factors Responsible for Poor Control of Asthma in the Middle East and Africa Region. SABA = Short-acting β-agonists

Figure 1 Factors Responsible for Poor Control of Asthma in the Middle East and Africa Region. SABA = Short-acting β-agonists

Figure 2 Cardinal Elements for Assessment of Asthma

Figure 2 Cardinal Elements for Assessment of Asthma

Figure 3.1 Approach for Management of Asthma in Adults and Adolescents as per GINA Guidelines.[1] HDM-SLIT = House dust mitesublingual immunotherapy, ICS = Inhaled corticosteroid, IgE = Immunoglobulin E, IL = Interleukin, LABA = Long-acting bronchodilator, LAMA = Long-acting muscarinic antagonist, LTRA = Leukotriene receptor antagonist, OCS = Oral corticosteroid, SABA = Short-acting beta-agonist show full caption

Figure 3.1 Approach for Management of Asthma in Adults and Adolescents as per GINA Guidelines.[1] HDM-SLIT = House dust mitesublingual immunotherapy, ICS = Inhaled corticosteroid, IgE = Immunoglobulin E, IL = Interleukin, LABA = Long-acting bronchodilator, LAMA = Long-acting muscarinic antagonist, LTRA = Leukotriene receptor antagonist, OCS = Oral corticosteroid, SABA = Short-acting beta-agonist show full caption

Figure 3.2 Approach for Management of Asthma in Adults and Adolescents as per SINA Guidelines.[69] ICS = Inhaled corticosteroid, IgE = Immunoglobulin E, IL = Interleukin, LABA = Long-acting bronchodilator, LAMA = Long-acting muscarinic antagonist, LTRA = Leukotriene receptor antagonist, SABA = Short-acting beta-agonist show full caption

Figure 3.2 Approach for Management of Asthma in Adults and Adolescents as per SINA Guidelines.[69] ICS = Inhaled corticosteroid, IgE = Immunoglobulin E, IL = Interleukin, LABA = Long-acting bronchodilator, LAMA = Long-acting muscarinic antagonist, LTRA = Leukotriene receptor antagonist, SABA = Short-acting beta-agonist show full caption

Similar articles

It is time to change the way we manage mild asthma: an update in GINA 2019.

Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK.Respir Res. 2019 Aug 14;20(1):183. doi: 10.1186/s12931-019-1159-y.PMID: 31412856 Free PMC article.

Usage Patterns of Short-Acting β2-Agonists and Inhaled Corticosteroids in Asthma: A Targeted Literature Review.

Amin S, Soliman M, McIvor A, Cave A, Cabrera C.J Allergy Clin Immunol Pract. 2020 Sep;8(8):2556-2564.e8. doi: 10.1016/j.jaip.2020.03.013. Epub 2020 Mar 31.PMID: 32244024

The management of mild asthma.

O'Byrne PM, Reddel HK, Beasley R.Eur Respir J. 2021 Apr 8;57(4):2003051. doi: 10.1183/13993003.03051-2020. Print 2021 Apr.PMID: 33093120 Review.

Overprescription of short-acting β2-agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study.

Al Zaabi A, Busaidi N, Al Mutairy S, Yorgancıoğlu A, Aksu K, Al-Jahdali H, Wali S, Elsayed M, Beekman MJ.Expert Rev Respir Med. 2022 Jul;16(7):833-847. doi: 10.1080/17476348.2022.2099841. Epub 2022 Aug 24.PMID: 35848074

As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?

Domingo C, Rello J, Sogo A.Drugs. 2019 Nov;79(16):1729-1737. doi: 10.1007/s40265-019-01202-0.PMID: 31584145 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Global Strategy for Asthma Management and Prevention: GINA. 2020. [Last accessed on 2021 Mar 26]. Available from: https://ginasthma.org/wp-content/ uploads/2020/04/GINA-2020-full-report_... .
  2.  
    1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691–706. - PMC - PubMed
  3.  
    1. Subbarao P, Mandhane PJ, Sears MR. Asthma: Epidemiology, etiology and risk factors. CMAJ. 2009;181:E181–90. - PMC - PubMed
  4.  
    1. de Marco R, Marcon A, Jarvis D, Accordini S, Almar E, Bugiani M, et al. Prognostic factors of asthma severity: A 9-year international prospective cohort study. J Allergy Clin Immunol. 2006;117:1249–56. - PubMed
  5.  
    1. Bener A, Abdulrazzaq YM, Al-Mutawwa J, Debuse P. Genetic and environmental factors associated with asthma. Hum Biol. 1996;68:405–14. - PubMed
  6.  
    1. Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health. 2009;6:17. - PMC - PubMed
  7.  
    1. WHO Fact Sheets Asthma. 2021. [Last accessed on 2021 Jun 28]. Available from: https://www. who.int/news-room/fact-sheets/detail/asthma .
  8.  
    1. Masoli M, Fabian D, Holt S, Beasley R Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–78. - PubMed
  9.  
    1. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3–8. - PubMed
  10.  
    1. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1. - PMC - PubMed
  11.  
    1. Şekerel BE, Türktaş H, Bavbek S, Øksüz E, Malhan S. Economic burden of pediatric asthma in turkey: A cost of illness study from payer perspective. Turk Thorac J. 2020;21:248–54. - PMC - PubMed
  12.  
    1. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: The REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. - PMC - PubMed
  13.  
    1. Al-Jahdali H, Wali S, Salem G, Al-Hameed F, Almotair A, Zeitouni M, et al. Asthma control and predictive factors among adults in Saudi Arabia: Results from the Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population study. Ann Thorac Med. 2019;14:148–54. - PMC - PubMed
  14.  
    1. Tarraf H, Al-Jahdali H, Al Qaseer AH, Gjurovic A, Haouichat H, Khassawneh B, et al. Asthma control in adults in the Middle East and North Africa: Results from the ESMAA study. Respir Med. 2018;138:64–73. - PubMed
  15.  
    1. Mungan D, Aydin O, Mahboub B, Albader M, Tarraf H, Doble A, et al. Burden of disease associated with asthma among the adult general population of five Middle Eastern countries: Results of the SNAPSHOT program. Respir Med. 2018;139:55–64. - PubMed
  16.  
    1. Bassam M, Behbehani N, Farouk H, Alsayed M, Montestruc F, Al-Jahdali H, et al. Adherence to medication among adult asthma patients in the Middle East and North Africa: Results from the ESMAA study. Respir Med. 2021;176:106244. - PubMed
  17.  
    1. Khadadah M, Mahboub B, Al-Busaidi NH, Sliman N, Soriano JB, Bahous J. Asthma insights and reality in the Gulf and the near East. Int J Tuberc Lung Dis. 2009;13:1015–22. - PubMed
  18.  
    1. Sekerel BE, Gemicioglu B, Soriano JB. Asthma insights and reality in Turkey (AIRET) study. Respir Med. 2006;100:1850–4. - PubMed
  19.  
    1. Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, et al. Prevalence and risk factors of allergies in turkey (PARFAIT): Results of a multicentre cross-sectional study in adults. Eur Respir J. 2009;33:724–33. - PubMed
  20.  
    1. Benkheder A, Bouacha H, Nafti S, Taright S, El Ftouh M, Yassine N, et al. Control of asthma in the Maghreb: Results of the AIRMAG study. Respir Med. 2009;103(Suppl 2):S12–20. - PubMed
  21.  
    1. Al-Jahdali HH, Al-Hajjaj MS, Alanezi MO, Zeitoni MO, Al-Tasan TH. Asthma control assessment using asthma control test among patients attending 5 tertiary care hospitals in Saudi Arabia. Saudi Med J. 2008;29:714–7. - PubMed
  22.  
    1. Bener A, Abdulrazzaq YM, Debuse P, Al-Mutawwa J. Prevalence of asthma among Emirates school children. Eur J Epidemiol. 1994;10:271–8. - PubMed
  23.  
    1. Owayed A, Behbehani N, Al-Momen J. Changing prevalence of asthma and allergic diseases among Kuwaiti children.An ISAAC Study (Phase III) Med Princ Pract. 2008;17:284–9. - PubMed
  24.  
    1. Tarraf H, Aydin O, Mungan D, Albader M, Mahboub B, Doble A, et al. Prevalence of asthma among the adult general population of five Middle Eastern countries: Results of the SNAPSHOT program. BMC Pulm Med. 2018;18:68. - PMC - PubMed
  25.  
    1. Levy ML, Andrews R, Buckingham R, Evans H, Francis C, Houston R, et al. London: Royal College of Physicians; 2014. [Last accessed on 2021 Mar 26]. Confidential Enquiry Report. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD) Available from: https://www.rcplondon.ac.uk/sites/default/files/ why-asthma-still-kills-... .
  26.  
    1. Olaguibel JM, Quirce S, Juliá B, Fernández C, Fortuna AM, Molina J, et al. Measurement of asthma control according to Global Initiative for Asthma guidelines: A comparison with the Asthma Control Questionnaire. Respir Res. 2012;13:50. - PMC - PubMed
  27.  
    1. O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: Time for a new approach? Eur Respir J. 2017;50:1701103. - PubMed
  28.  
    1. Tuomisto LE, Ilmarinen P, Niemelä O, Haanpää J, Kankaanranta T, Kankaanranta H. A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study. Respir Med. 2016;117:223–9. - PubMed
  29.  
    1. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: The INSPIRE study. BMC Pulm Med. 2006;6:13. - PMC - PubMed
  30.  
    1. Vermeire PA, Rabe KF, Soriano JB, Maier WC. Asthma control and differences in management practices across seven European countries. Respir Med. 2002;96:142–9. - PubMed
  31.  
    1. Miles C, Arden-Close E, Thomas M, Bruton A, Yardley L, Hankins M, et al. Barriers and facilitators of effective self-management in asthma: Systematic review and thematic synthesis of patient and healthcare professional views. NPJ Prim Care Respir Med. 2017;27:57. - PMC - PubMed
  32.  
    1. Gruffydd-Jones K, Hansen K. Working for better asthma control: How can we improve the dialogue between patients and healthcare professionals? Adv Ther. 2020;37:1–9. - PubMed
  33.  
    1. Haughney J, Barnes G, Partridge M, Cleland J. The living & breathing study: A study of patients’ views of asthma and its treatment. Prim Care Respir J. 2004;13:28–35. - PMC - PubMed
  34.  
    1. Noibi S, Mohy A, Gouhar R, Shaker F, Lukic T, Al-Jahdali H. Asthma control factors in the Gulf Cooperation Council (GCC) countries and the effectiveness of ICS/LABA fixed dose combinations: A dual rapid literature review. BMC Public Health. 2020;20:1211. - PubMed
  35.  
    1. Al-Moamary MS, Alhaider SA, Alangari AA, Idrees MM, Zeitouni MO, Al Ghobain MO, et al. The Saudi Initiative for Asthma – 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2021;16:4–56. - PubMed
  36.  
    1. Aksu F, Şahin AD, Şengezer T, Aksu K. Effect of training by a physician on dynamics of the use of inhaler devices to improve technique in patients with obstructive lung diseases. Allergy Asthma Proc. 2016;37:98–102. - PubMed
  37.  
    1. Caminati M, Vaia R, Furci F, Guarnieri G, Senna G. Uncontrolled asthma: Unmet needs in the management of patients. J Asthma Allergy. 2021;14:457–66. - PubMed
  38.  
    1. Moradi-Lakeh M, El Bcheraoui C, Daoud F, Tuffaha M, Kravitz H, Al Saeedi M, et al. Prevalence of asthma in Saudi adults: Findings from a national household survey, 2013. BMC Pulm Med. 2015;15:77. - PubMed
  39.  
    1. National Institute for Health and Care Excellence (NICE), Asthma Diagnosis, Monitoring and Chronic Asthma. 2020. [Last accessed on 2021 Mar 26]. Available from: https://www.nice.org.uk/guidance/ng80/resources/ asthma-diagnosis -monit... .
  40.  
    1. Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Effective asthma management: Is it time to let the AIR out of SABA? J Clin Med. 2020;9:E921. - PubMed
  41.  
    1. British Thoracic Society. Asthma: Better Lung Health for All. [Last accessed on 2021 Mar 29]. Available from: https://www.brit-thoracic.org.uk/ quality-improvement/guidelines/asthma .
  42.  
    1. Pollart SM, Elward KS. Overview of changes to asthma guidelines: Diagnosis and screening. Am Fam Physician. 2009;79:761–7.
  43.  
    1. Schuler M, Faller H, Wittmann M, Schultz K. Asthma Control Test and Asthma Control Questionnaire: Factorial validity, reliability and correspondence in assessing status and change in asthma control. J Asthma. 2016;53:438–45. - PubMed
  44.  
    1. Zeru TG, Engidawork E, Berha AB. Assessment of asthma control and quality of life among asthmatic patients attending armed forces referral and teaching hospital, Addis Ababa, Ethiopia. Pulm Med. 2020;2020:5389780. - PubMed
  45.  
    1. Tommola M, Ilmarinen P, Tuomisto LE, Lehtimäki L, Niemelä O, Nieminen P, et al. Cumulative effect of smoking on disease burden and multimorbidity in adult-onset asthma. Eur Respir J. 2019;54:1801580. - PubMed
  46.  
    1. Aaron SD, Fergusson D, Dent R, Chen Y, Vandemheen KL, Dales RE. Effect of weight reduction on respiratory function and airway reactivity in obese women. Chest. 2004;125:2046–52. - PubMed
  47.  
    1. Larsson K, Kankaanranta H, Janson C, Lehtimäki L, Ställberg B, Løkke A, et al. Bringing asthma care into the twenty-first century. NPJ Prim Care Respir Med. 2020;30:25. - PubMed
  48.  
    1. Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017;4:CD012226. - PubMed
  49.  
    1. Grembiale RD, Pelaia G, Naty S, Vatrella A, Tranfa CM, Marsico SA. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm Pharmacol Ther. 2002;15:463–6. - PubMed
  50.  
    1. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325:388–92. - PubMed
  51.  
    1. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57:880–4. - PubMed
  52.  
    1. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332–6. - PubMed
  53.  
    1. Beasley R, Bird G, Harper J, Weatherall M. The further paradoxes of asthma management: Time for a new approach across the spectrum of asthma severity. Eur Respir J. 2018;52:1800694. - PubMed
  54.  
    1. FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–40. - PubMed
  55.  
    1. Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: A nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55:1901872. - PubMed
  56.  
    1. Rodrigo GJ, Rodrigo C. Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma. Emerg Med J. 2005;22:404–8. - PubMed
  57.  
    1. Gupta P, O’Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: Recommendations for prescribing. Drugs Aging. 2008;25:415–43. - PubMed
  58.  
    1. Kaplan AG, Correia-de-Sousa J, McIvor A Global Policy Steering Group on Improving Asthma Outcomes. Global quality statements on reliever use in asthma in adults and children older than 5 years of age. Adv Ther. 2021;38:1382–96. - PubMed
  59.  
    1. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392–7. - PubMed
  60.  
    1. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet. 2003;361:1071–6. - PubMed
  61.  
    1. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378:1865–76. - PubMed
  62.  
    1. Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378:1877–87. - PubMed
  63.  
    1. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380:2020–30. - PubMed
  64.  
    1. Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): A 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394:919–28. - PubMed
  65.  
    1. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99. - PubMed
  66.  
    1. Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32:545–54. - PubMed
  67.  
    1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73. - PubMed
  68.  
    1. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: A fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53:1901046. - PubMed
  69.  
    1. Cruz ÁA, Barile S, Nudo E, Brogelli L, Guller P, Papi A. ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: An international survey on GINA strategy. Asthma Res Pract. 2021;7:1. - PubMed
  70.  
    1. Al-Moamary MS, Al-Hajjaj MS, Idrees MM, Zeitouni MO, Alanezi MO, Al-Jahdali HH, et al. The Saudi initiative for asthma. Ann Thorac Med. 2009;4:216–33. - PubMed
  71.  
    1. Furuhashi K, Fujisawa T, Hashimoto D, Kamiya Y, Yasui H, Karayama M, et al. Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: A randomized crossover trial. J Asthma Allergy. 2019;12:253–61. - PubMed
  72.  
    1. Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid/long-acting ß-agonist for asthma. J Allergy Clin Immunol Pract. 2019;7:1488–96.e7. - PubMed
  73.  
    1. Averell CM, Stanford RH, Laliberté F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58:102–11. - PubMed
  74.  
    1. Busse WW, O’Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: A randomised trial. Thorax. 2013;68:513–20. - PubMed
  75.  
    1. O’Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43:773–82. - PubMed
  76.  
    1. Woodcock A, Bleecker ER, Lötvall J, O’Byrne PM, Bateman ED, Medley H, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: A randomized trial. Chest. 2013;144:1222–9. - PubMed
  77.  
    1. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013;9:CD000052.
  78.  
    1. Newman KB, Milne S, Hamilton C, Hall K. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest. 2002;121:1036–41. - PubMed
  79.  
    1. Tavakoli H, Mark FitzGerald J, Lynd LD, Sadatsafavi M. Predictors of inappropriate and excessive use of reliever medications in asthma: A 16-year population-based study. BMC Pulm Med. 2018;18:33. - PubMed
  80.  
    1. Blakeston S, Harper G, Zabala Mancebo J. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma. J Asthma. 2021;58:1094–1101. W. - PubMed
  81.  
    1. Chan AH, Katzer CB, Horne R, Haughney J, Correia de Sousa J, Williams S, et al. SABA Reliance Questionnaire (SRQ): Identifying patient beliefs underpinning reliever overreliance in asthma. J Allergy Clin Immunol Pract. 2020;8:3482–9.e1. - PubMed

Page Navigation